كالجاري، ألبرتا ونيويورك, July 16, 2025 (GLOBE NEWSWIRE) —
Read more »
The New Science of Superhumans: The BioSport™ AI System Unlocks Hidden Athlete Potential
CALGARY, Alberta and NEW YORK, July 15, 2025 (GLOBE NEWSWIRE) — In a move that signals a new era in athlete safety and performance science, The BioSport™ Health Inc, a precision health technology company, today unveiled its [...] Read more »
الإمارات العربية المتحدة تعتمد المكمل Longevity+ من BioAro، فاتحة المجال إلى إمكانات تسويقية كبيرة في مجال الصحة الوقائية العالمية
كالجاري، ألبرتا, July 08, 2025 (GLOBE NEWSWIRE) — في خطوة مهمة [...] Read more »
UAE Approves BioAro’s Longevity+ Supplement, Signaling Major Market Potential in Global Preventive Health
CALGARY, Alberta, July 08, 2025 (GLOBE NEWSWIRE) — In a significant move that bridges biotechnology, preventive health, and global wellness trends, Canadian biotech company BioAro has announced the launch [...] Read more »
Les Émirats arabes unis approuvent le complément Longevity+ de BioAro, ouvrant la voie à un fort potentiel sur le marché mondial de la santé préventive
CALGARY, Alberta, 08 juill. 2025 (GLOBE NEWSWIRE) — Dans une avancée majeure à l’intersection de la biotechnologie, de la santé préventive et des tendances commerciales en matière [...] Read more »
OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting
MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) — OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”) today announced that new pharmacologic and pharmacokinetic in [...] Read more »
Fortrea & Emery Pharma Anunciam Colaboração Estratégica para Fornecer Estudos de Interação Medicamentosa Usando Rifampicina em Conformidade com o FDA
DURHAM, N.C., June 24, 2025 (GLOBE NEWSWIRE) — A Read more »
Fortrea et Emery Pharma annoncent une collaboration stratégique visant à mener des études sur les interactions médicamenteuses répondant aux normes de la FDA en utilisant la rifampicine
DURHAM, Caroline du Nord, 24 juin 2025 (GLOBE NEWSWIRE) — Read more »
Fortrea und Emery Pharma kündigen strategische Zusammenarbeit zur Durchführung FDA-konformer Arzneimittelwechselwirkungsstudien mit Rifampin an
Durham, North Carolina, June 24, 2025 (GLOBE NEWSWIRE) — Read more »
Fortrea & Emery Pharma Announce Strategic Collaboration to Deliver FDA Compliant Drug-Drug-Interaction Studies Using Rifampin
DURHAM, N.C., June 24, 2025 (GLOBE NEWSWIRE) — Read more »